Clinical Trial Update: Prospective Observational Study of Febrile Neutropenia (FN) and Pegfilgrastim Primary Prophylaxis in Breast Cancer and Non-Hodgkin's Lymphoma Patients Receiving High (>20%) FN-risk Chemotherapy

View source ↗

Summary

This completed prospective observational study evaluated febrile neutropenia and pegfilgrastim primary prophylaxis in breast cancer and Non-Hodgkin lymphoma pat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Non-hodgkin Lymphoma

Drugs mentioned

• NEULASTA (pegfilgrastim)

Snippet

Sponsor: Amgen | Conditions: Chemotherapy-induced Febrile Neutropenia | Status: COMPLETED | Results posted: 2018-07-23